Teriflunomide (trade name Aubagio, marketed by Sanofi) is the active metabolite of leflunomide. Teriflunomide was investigated in the Phase III clinical trial TEMSO as a medication for multiple sclerosis (MS). The study was completed in July 2010. 2-year results were positive. However, the subsequent TENERE head-to-head comparison trial reported that \"although permanent discontinuations [of therapy] were substantially less common among MS patients who received teriflunomide compared with interferon beta-1a, relapses were more common with teriflunomide.\" The drug was approved by the FDA on September 13, 2012 and in the European Union on August 26, 2013.

CAS：163451-81-8
中文别名：(Z)-2-氰基-3-羟基-N-(4-(三氟甲基)苯基)丁-2-烯酰胺;A77 1726;Aubagio;(2Z)-2-氰基-3-羟基-N-[4-(三氟甲基)苯基]丁-2-烯酰胺;
英文别名：(2Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide;(Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)but-2-enamide;Teriflunomide;
分子式：C12H9F3N2O2
分子量：270.207
精确质量：270.062
Psa：73.12
Logp：3.07248

密度：1.4±0.1g/cm3
沸点：410.8±45.0°Cat760mmHg
闪点：202.3±28.7°C
蒸汽压：0.0±1.0mmHgat25°C
折射率：1.552
储存条件：-20°C

海关编码：2942000000
危险性描述：H302
信号词：Warning
危险标志：GHS07